BioPharmSignal logoBioPharmSignal

Biotech News

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Conference / presentation

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21 st Annual Healthcare Conference Thursday, Sept. 10 at 9:30 a.m. ET 2026 Cantor Global Healthcare Conference Friday, Sept.

Related news

ARWRArrowhead Pharmaceuticals2026-09-03 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

PHARPharming Group2026-09-09 06:00 EST

Pharming Group to participate in September investor conferences

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

ETONEton Pharmaceuticals2026-08-27 10:50 EST

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

RAREUltragenyx Pharmaceutical2026-06-03 20:30 EST

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

PHARPharming Group2026-06-02 06:00 EST

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

CRNXCrinetics Pharmaceuticals2026-05-22 20:05 EST

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

PTCTPTC Therapeutics, Inc.2026-07-16 12:00 EST

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-08-24 12:00 EST

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTCTPTC Therapeutics, Inc.2026-08-12 20:01 EST

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-07-16 12:00 EST

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

Stock data

Close
68.00 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States